12,226 Shares in Guardant Health, Inc. $GH Acquired by Trillium Asset Management LLC

Trillium Asset Management LLC purchased a new stake in shares of Guardant Health, Inc. (NASDAQ:GH – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 12,226 shares of the company’s stock, valued at approximately $2,181,000.

Other institutional investors have also recently bought and sold shares of the company. Ninepoint Partners LP acquired a new stake in shares of Guardant Health in the second quarter valued at $2,853,000. Orbimed Advisors LLC bought a new position in shares of Guardant Health in the first quarter valued at about $40,199,000. GSA Capital Partners LLP bought a new position in shares of Guardant Health in the second quarter valued at about $1,772,000. Eagle Health Investments LP acquired a new position in Guardant Health during the 2nd quarter worth about $45,112,000. Finally, SWS Partners acquired a new position in Guardant Health during the 2nd quarter worth about $11,190,000. Institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In other Guardant Health news, Director Steve E. Krognes sold 6,674 shares of the company’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $175.74, for a total transaction of $1,172,888.76. Following the transaction, the director directly owned 7,906 shares in the company, valued at approximately $1,389,400.44. This represents a 45.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CTO Darya Chudova sold 7,738 shares of the company’s stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total transaction of $1,377,364.00. Following the transaction, the chief technology officer owned 70,635 shares in the company, valued at approximately $12,573,030. The trade was a 9.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 53,039 shares of company stock valued at $9,088,877 in the last three months. Company insiders own 5.60% of the company’s stock.

Guardant Health Stock Performance

NASDAQ GH opened at $151.70 on Monday. The stock has a fifty day moving average of $168.64 and a 200-day moving average of $132.99. The stock has a market capitalization of $20.52 billion, a P/E ratio of -41.22 and a beta of 1.67. Guardant Health, Inc. has a 52 week low of $74.55 and a 52 week high of $191.05.

Guardant Health (NASDAQ:GH – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.46. The firm had revenue of $360.98 million for the quarter, compared to the consensus estimate of $350.72 million. The company’s revenue was up 36.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) EPS. Equities research analysts forecast that Guardant Health, Inc. will post -3.08 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have commented on the stock. Roth Capital started coverage on shares of Guardant Health in a report on Thursday, October 22nd. They set a “buy” rating and a $200.00 price objective on the stock. BTIG Research boosted their target price on shares of Guardant Health from $195.00 to $210.00 and gave the stock a “buy” rating in a research note on Tuesday, October 27th. UBS Group upped their target price on shares of Guardant Health from $175.00 to $225.00 and gave the stock a “buy” rating in a research report on Wednesday, September 9th. Stephens upped their target price on shares of Guardant Health from $170.00 to $195.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 4th. Finally, Mizuho increased their price target on shares of Guardant Health from $175.00 to $200.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $190.88.

View Our Latest Research Report on GH

Guardant Health Company Profile

(Free Report)

Guardant Health is a precision oncology company that develops blood- and tissue-based tests to help guide cancer care. Founded in 2012 by Helmy Eltoukhy and AmirAli Talasaz, the company focuses on using genomic information to support cancer detection, treatment selection and disease monitoring. Its products include Guardant360 tests, which analyze tumor-related genetic changes to help inform treatment decisions, and Guardant Reveal, which is designed to detect residual or recurring cancer after treatment.

See Also

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GH – Free Report).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.